In fact, Viking just gave investors an update which firms up its status as a very promising company. Here's what it reported, ...

After 20 seasons of ownership, the Wilf family have a winning team, an always-sold-out stadium and a growing real estate ...

The biotech’s liver-disease treatment is also viewed as best-in-class, earning it a full slate of buy ratings from analysts.

Sea and Spotify saw the largest valuation bumps among US-listed stocks covered by Morningstar analysts. Maintaining independence and editorial freedom is essential to our mission of empowering ...

B. Riley analyst Mayank Mamtani initiated coverage of Viking Therapeutics (VKTX) with a Buy rating and $109 price target The firm has ...

Analyst Joseph Pantginis from H.C. Wainwright reiterated a Buy rating on Viking Therapeutics (VKTX – Research Report) and keeping the price ...

Viking Holdings Ltd (the “Company” or “Viking”) (NYSE: VIK) today reported financial results for the third quarter ended September 30, 2024. “The strength of our one Viking brand and our loyal guests ...